Drug Trial Radar · NCT03103568
A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Mar 28, 2017
Primary completion
Jun 10, 2017
Study completion Jul 24, 2017
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open-label, non-randomized, 2-arm, 2-period fixed sequence phase 1 study to evaluate the potential inhibition of nitisinone on cytochrome P450 2C9, 2D6, and 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers
Conditions
- Drug Drug Interaction
Interventions
Nitisinone in Arm ADrug
4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
TolbutamideDrug
A 500 mg tablet is given as single oral dose 2 weeks apart.
MetoprololDrug
A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
ChlorzoxazoneDrug
A 250 mg tablet is given as single oral dose 2 weeks apart.
FurosemideDrug
A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
Nitisinone in Arm BDrug
4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the curve (AUC) infinity for CYP2C9 (tolbutamide) substrateTime frame: Blood samples will be obtained the following times in relation to tolbutamide administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36 and 48 h post-dose.
- AUC infinity for CYP2D6 (metoprolol) substrateTime frame: Blood samples will be obtained the following times in relation to metoprolol administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9, 11, 15 and 23 h post-dose.
- AUC infinity for CYP2E1 (chlorzoxazone) substrateTime frame: Blood samples will be obtained the following times in relation to chlorzoxazone administration: predose and, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 7, 9 and 11 h post-dose.
- AUC infinity for OAT1/OAT3 (furosemide) substrateTime frame: Blood samples will be obtained the following times in relation to furosemide administration: predose and, 5, 10, 15, 20, 30, 45 minutes, 1, 2, 3, 4, 6, and 8 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PAREXEL EPCU Berlin
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.